Watch for Jorveza, a New Med for Eosinophilic Esophagitis

April 2021

Jorveza (budesonide) orodispersible tabs will be the first treatment approved for eosinophilic esophagitis (EoE).

This is a chronic allergic condition in kids and adults that causes inflammation along the esophagus. It can result in symptoms such as trouble swallowing, chest pain, and vomiting.

Patients with EoE often get an inhaled steroid (Flovent HFA, etc) with directions to SWALLOW each puff, instead of inhale...or to mix contents of a steroid nebule into a slurry and swallow.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Dispensing Don't Leave Off Key Details in Rx Sigs
COVID-19 Listen for New Questions About COVID-19 Vaccines
COVID-19 Know Which COVID-19 Rxs May Be Too Soon for Prime Time
HIV & AIDS Understand the New INSTI HIV Self Test for Use at Home
Headache Help Aimovig Patients Get Set Up With a Blood Pressure Monitor
Bowel Preps Avoid Mix-Ups With Bowel Preps
Diabetes Stay Alert for Patients With Diabetes Who May Need a Statin
Respiratory & Allergy Watch for Jorveza, a New Med for Eosinophilic Esophagitis
Immunosuppressives Be Aware of New Safety Issues With Xeljanz

Watch for Jorveza, a New Med for Eosinophilic Esophagitis

Practical advice for a better career, with unlimited access to CE

Table of Contents